Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC
Conditions
- Non-Small Cell Lung Cancer
Interventions
- DRUG: Osimertinib
- DRUG: Alectinib
- DRUG: TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy
Sponsor
Guangdong Association of Clinical Trials
Collaborators